Bobsilentbob

Jollyrancher

Spiro

Rockeye

any of them still around?

Summer Street must have missed this part of the call:

.

.

In summary, the 171 trial met the primary efficacy endpoint of non-inferior reduction in A1c when comparing AFREZZA -Gen2 to insulin aspart as well as the primary safety endpoint of showing a comparable mean change in FEV1 over the treatment period between the Gen2 and the MedTone treatment groups.

• Mannkind ( target="_blank">negative note out of Summer Street this morning.


• The firm appears to be suspicious of the results of the drug developer's Phase III AFFINITY 1 trial, after they released results on the injectable insulin and Dreamboat arms but withheld the results on the Medtone C-arm.


• Releasing data on only two of the three arms of the trial like that is unprecedented.


• If the results on the Medtone C-arm aren't worthy of presenting and inhalers aren't equivalent, then Summer Street feels there's not enough safety information to approve Dreamboat.

This was buried at the bottom of their relase today:

MannKind will host a conference call to discuss the second quarter financial results and recent clinical trial results at 4:00 PM (Eastern Time) on August 14, 2013. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer; and Senior Vice President, Clinical Sciences, Robert Baughman.
To participate in the live call by telephone, please dial (800) 447-0521 or (847) 413-3238 and use the participant passcode: 34087263. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 3408 7263#. A replay will also be available on MannKind's website for 14 days.

It's already starting. AF & his posse are hammering results on Twitter. Hopefully Al will hammer them with a great CC.

I'm guilty, sold about half in pre-market. I put in a buy order at a lower price with the proceeds. I don't think the shorts will give up easily, I'm sure the articles from Kliff & AF will start soon. I still hold plenty of shares for the unexpected good news events that may pop up. Hopefully I'll be fully re-loaded by then.

Results were excellent!